A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.

This study has been completed.
Information provided by:
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
First received: September 16, 2008
Last updated: April 2, 2015
Last verified: April 2015
To determine the effects of WelChol tablets on serum lipids, lipoproteins, apolipoproteins, and lipoprotein particle size in patients who were stabilized on atorvastatin therapy for at least 4 weeks.

Condition Intervention Phase
Drug: colesevelam HCl tablets, and atorvastatin tablets
Drug: colesevelam HCl placebo tablets and atorvastatin tablets
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of WelChol as an Add-on to Atorvastatin Therapy

Resource links provided by NLM:

Further study details as provided by Daiichi Sankyo Inc.:

Primary Outcome Measures:
  • The primary efficacy parameter is the percent change in LDL-C from baseline to endpoint. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The absolute change in LDL-C from baseline to endpoint [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • The absolute change and % change in total cholesterol [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • The absolute change and % change in triglycerides [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • The absolute change and % change in HDL-C [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • The absolute change and % change in C-reactive protein [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 65
Study Start Date: November 2002
Study Completion Date: April 2005
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
colesevelam tablets and atorvastatin tablets
Drug: colesevelam HCl tablets, and atorvastatin tablets
colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
Placebo Comparator: 2
colesevelam HCl placebo tablets and atorvastatin tablets
Drug: colesevelam HCl placebo tablets and atorvastatin tablets
colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female > or greater than 18 years of age
  • On a stable dose of atorvastatin
  • LDL-C > or = to 115 mg/dL and < or = to 250 mg/dL
  • TG < or = to 300 mg/dL
  • Women are not pregnant or breast-feeding or planning to become pregnant
  • Women of child-bearing potential had a hysterectomy or tubal-ligation, or
  • women were post menopausal, or
  • women practiced an acceptable method of contraception as specified in the protocol

Exclusion Criteria:

  • BMI > 40 kg/m2
  • History of allergic or toxic reaction to colesevelam HCl
  • History of swallowing disorders
  • Any serious disorder that could impact the conduct of the study
  • History of drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00754507

United States, California
Los Angeles, California, United States
United States, Colorado
Castle Rock, Colorado, United States
United States, Florida
Jacksonville, Florida, United States
Pembroke Pines, Florida, United States
St. Petersburg, Florida, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, New York
Rochester, New York, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
United States, Tennessee
Bartlett, Tennessee, United States
United States, Virginia
Norfolk, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Seattle, Washington, United States
Sponsors and Collaborators
Daiichi Sankyo Inc.
  More Information

No publications provided

Responsible Party: Senior Director of Metabolic Research, Daiichi Sankyo, Inc.
ClinicalTrials.gov Identifier: NCT00754507     History of Changes
Other Study ID Numbers: WEL-406 
Study First Received: September 16, 2008
Last Updated: April 2, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2016